Cross-talk between the IDO-kynurenine and NRLP3 inflammasome pathways in experimental NASH
AASLD LiverLearning®, Fabio Marra, 195593
New approaches to hepatic edema by tolvaptan in the elderly population of liver cirrhosis
AASLD LiverLearning®, Hitoshi Yoshiji, 195338
Oral administration of CardioAid and LunaRichX plant sterols alleviates liver damage in a high-fat diet NASH model
AASLD LiverLearning®, Yaron Ilan, 195594
Non-selective beta-blockers and acute kidney injury related in decompensated cirrhosis.
AASLD LiverLearning®, Jessica Guerrero Cabrera, 195339
The Physiological, Pathological and Molecular Basis of Nonalcoholic Steatohepatitis Associated Cardiomyopathy
AASLD LiverLearning®, Abdul Oseini, 195595
Hospital-Acquired Acute Kidney Injury in Patients with Cirrhosis: Predictors and Outcomes
AASLD LiverLearning®, Eric Orman, 195340
Promoted liver fibrosis and malignant phenotype in HCV/PDGF-C transgenic mice are accompanied by abnormal expression of the glycolysis-related gene pyruvate kinase M
AASLD LiverLearning®, Hikari Okada, 195353
Reverse translation of clinical biomarkers into experimental models of NASH
AASLD LiverLearning®, Martine Morrison, 195609
Targeting aspartate β-hydroxylase suppresses cholangiocarcinoma metastasis
AASLD LiverLearning®, Jack Wands, 195354
Establishment of mouse Mac-2 binding protein ELISA and its application for mouse chronic liver disease models
AASLD LiverLearning®, Yoshihiro Kamada, 195610
NLRC4 inflammasome contributes to the growth of liver metastasis in non-alcoholic fatty liver disease through modulating M1-M2 phenotype
AASLD LiverLearning®, Koichiro Ohashi, 195355
Introducing a new pre-clinical rat model of advanced steatohepatitis that mimics the main characteristics of the human disease.
AASLD LiverLearning®, Jordi Gracia-Sancho, 195611
Dysbiosis of gut microbiota promote inflammation and carcinogenesis in the liver
AASLD LiverLearning®, Noriho Iida, 195356
MYL6B, a myosin light chain, promote p53 degradation and drive HCC development by interacting with MDM2 and p53
AASLD LiverLearning®, Xing-Wang Xie, 195369
Gemcabene Attenuates the NAFLD Activity and Fibrosis Scores, and Downregulates Hepatic Inflammatory Genes in the STAMTM Murine Model of NASH-HCC
AASLD LiverLearning®, Daniela Oniciu, 195625
The Wnt Target Gene CLAUDIN-2 Regulates Tumorigenesis of Combined Hepatocellular-Cholangiocarcinoma Cells
AASLD LiverLearning®, Hironori Koga, 195370
Effects of beta-carotene on diet induced non-alcoholic steatohepatitis in mice
AASLD LiverLearning®, Tsuyoshi Chiba, 195626
The significance of Sox2 expression in hepatocellular carcinoma occurring on liver cirrhosis
AASLD LiverLearning®, Razvan Iacob, 195371
Novel Nonalcoholic Fatty Liver disease zebrafish model induced by Western Style Diet and aging.
AASLD LiverLearning®, Dalia David Niv, 195627
A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma
AASLD LiverLearning®, Chen Liu, 195372
Continuous hepatocyte apoptosis accelerates diethylnitrosamine-induced liver tumor development
AASLD LiverLearning®, Yasutoshi Nozaki, 195385
Accuracy and Repeatability of Magnetic Resonance Imaging Based Volumetric Liver Fat Fraction Compared to Liver Histology and Magnetic Resonance Spectroscopy as Reference Standards
AASLD LiverLearning®, Miriam Vos, 195641
Strategies to inhibit MICA shedding in HCC cells for immunosurveillance
AASLD LiverLearning®, Jun Arai, 195386
Reductions in liver stiffness by magnetic resonance elastography (MRE) predict fibrosis improvement in a multi-center clinical trial of subjects with nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Rohit Loomba, 195642
Role of the protease-inhibitor SerpinB3 in the cholangiocarcinoma stem-like compartment
AASLD LiverLearning®, Fabio Marra, 195387
Associations of the Grade and Relative Dominance of Perisinusoidal versus Portal Fibrosis In Nonalcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, David Kleiner, 195643
Using CRISPR and Sleeping Beauty Transposons in Forward and Reverse Genetic Screens Aimed at Developing a Non-Human Primate Model of Hepatocellular Carcinoma
AASLD LiverLearning®, Chris Chen, 195388
Lipogranulomas, neutrophils and the progression of NAFLD to NASH and HCC
AASLD LiverLearning®, João Maurício, 195401
Hepatocellular Carcinoma (HCC) in Patients with Non-Cirrhotic and Cirrhotic Nonalcoholic Fatty Liver Disease.
AASLD LiverLearning®, Lara Dakhoul, 195657
Cancer metabolic reprogramming allows hepatocarcinoma cells to efficiently adapt to their microenvironment.
AASLD LiverLearning®, Shamir Cassim, 195402
Type 2 diabetes and anti-diabetic medications modify the risk of liver-related outcomes in subjects with non-alcoholic fatty liver disease and advanced fibrosis. Results of a multicenter international cohort study.
AASLD LiverLearning®, Luis Bertot, 195658
Targeting the Warburg effect prevents cancer metabolic reprogramming in hepatocellular carcinoma cells and promotes cell death.
AASLD LiverLearning®, Shamir Cassim, 195403
Latent Class Analysis Reveals Distinct Classes of Nonalcoholic Fatty Liver Disease
AASLD LiverLearning®, Veeral Ajmera, 195659
Extracellular signal-regulated kinase 5 (ERK5) regulates growth, migration and invasion of cholangiocarcinoma (CCA) cells.
AASLD LiverLearning®, Fabio Marra, 195404
Variability in Hepatitis B surface Antigen (HBsAg) Levels during Nucleos(t)ide (NUC) Therapy in Subgroups of Immune Active CHB Patients
AASLD LiverLearning®, Edward Gane, 195417
Hepatocellular carcinoma in non-alchoolic steatohepatitis (NASH): Clinical, histopathological aspects and immunohistochemical of metabolic and proliferative related-markers.
AASLD LiverLearning®, Priscila Campos, 195673
A Retrospective Nationwide Study on Hepatitis B Epidemiology and Genotypes. The Canadian HBV Network
AASLD LiverLearning®, Carla Coffin, 195418
Short and long-term survival of patients suffering from non-severe alcoholic hepatitis
AASLD LiverLearning®, Christophe Moreno, 195674
Serum HBsAg levels predict the severity of liver fibrosis among HBeAg-positive patients across all major HBV genotypes and among patients with low ALT levels: results from the SONIC-B cohort
AASLD LiverLearning®, Milan Sonneveld, 195419
Using Surveillance Data to Monitor Hepatitis B Reactivation in Patients Receiving Direct Acting Antivirals for Hepatitis C, New York City
AASLD LiverLearning®, Ann Winters, 195420
Prevalence and predictors of hepatitis B immunization in adults without immunity for hepatitis B from 1999-2014: a population-based study of 27,713 adults in the U.S.
AASLD LiverLearning®, Michael Le, 195433
Nonalcoholic Steatohepatitis (NASH) Impairs Ventricular Diastolic Distensibility And Function Independent Of Underlying Type 2 Diabetes Or Hypertension
AASLD LiverLearning®, Mohammad Siddiqui, 195689
Severe Acute Hepatitis B: Predictive Clinical and Demographic Factors
AASLD LiverLearning®, James Bailey, 195434
Long-term Clinical Outcomes and Mortality Related to Nonalcoholic Steatohepatitis: Predictions of a Mathematical Model
AASLD LiverLearning®, Sumeyye Samur, 195690
Hepatitis B Virus Reactivation Rate is Considerably High during Sorafenib Therapy without Antiviral Treatment in Patients with Advanced Hepatocellular Carcinoma
AASLD LiverLearning®, Hyung Joon Yim, 195435
Birth Cohort Effects on Cirrhosis Incidence from 1997-2015: A Population-based Study
AASLD LiverLearning®, Jennifer Flemming, 195691
Application of Different Hepatitis B Treatment Guidelines to a Cohort of Infected Adults
AASLD LiverLearning®, Ruth Link-Gelles, 195436
Distribution of hepatitis B virus genotypes in Spain during the period 1999-2016 (Preliminary data of GEHEP 010 Study)
AASLD LiverLearning®, Federico Garcia, 195449
Combining genetics and IR-DRF, a novel measurement of insulin resistance, in predicting histological features of nonalcoholic steatohepatitis
AASLD LiverLearning®, Christopher Danford, 195705
Assessing trends in hepatitis B virus (HBV) infection and immunity at a community health center with universal screening practices
AASLD LiverLearning®, Amy Tang, 195450
Evaluation with transient elastography and controlled attenuation parameter of a cohort of patients with chronic liver diseases admitted in a hepatology tertiary center
AASLD LiverLearning®, Maria C. Speranta Iacob, 195706
Statin Use is Independently Associated with Less Severe Liver Fibrosis in Patients with Chronic Hepatitis B
AASLD LiverLearning®, Kali Zhou, 195451
Reductions in hepatic proton density fat fraction (PDFF) predict histologic improvement in a multi-center clinical trial of subjects with nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Rohit Loomba, 195707
Performance of fibrosis biomarkers for stratifying hepatocellular carcinoma risk in patients under antiviral therapy for chronic hepatitis B
AASLD LiverLearning®, Sang-geul Lee, 195452
Awareness, knowledge and treatment acceptance of hepatitis B infection in Southeast Asia: a cross-sectional study
AASLD LiverLearning®, Kittiyod Poovorawan, 195465
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease
AASLD LiverLearning®, Chiara Rosso, 195721
Hospital Wide Electronic Medical Record (EMR) Aquisition of Country of Birth During Registration to Identify Patients At Risk for Hepatitis B and/or Hepatitis C Infection to Implement Automated Order Entry For Blood Testing and Provide Linkage to Care (LT
AASLD LiverLearning®, Andrew de la Torre, 195466
Association of sarcopenia with non-alcoholic fatty liver disease (NAFLD) and fibrosis models in US adults
AASLD LiverLearning®, Eric Kallwitz, 195722
Clinical evaluation of a newly developed chemiluminescence enzyme immunoassay for hepatitis B core antibody.
AASLD LiverLearning®, Takako Inoue, 195467
Increased urinary arsenic is associated with elevated ALT in U.S. adolescents and adults
AASLD LiverLearning®, Jennifer Frediani, 195723
Profile of serum alanine aminotransferase (ALT) levels in a cohort of inactive European hepatitis B (HBV) carriers: 4 years follow-up of a prospective longitudinal study (ALBATROS Study)
AASLD LiverLearning®, Viola Knop, 195468
Screening For Hepatitis B Virus In Patients Receiving Immunosuppressive Therapy
AASLD LiverLearning®, Ijlal Akbar Ali, 195481
Decrease of Platelet Count Predicts de novo Hepatocellular Carcinoma in Chronic Hepatitis B Patients Who Achieved Sustained Virological Effect Under Long-term Nucleos(t)ide Analogues
AASLD LiverLearning®, Rei Miyake, 195482
Hepatitis B virus infection after the implementation of the vaccine program in Israel
AASLD LiverLearning®, Eli Zuckerman, 195483
Characterization of circulating microparticles in cirrhotic patients and their evolution during a six-month follow-up period: a pilot study
AASLD LiverLearning®, Delphine Weil, 195484
The relationship between the plasma free amino acids and the pathological features in nonalcoholic fatty liver disease (NAFLD)
AASLD LiverLearning®, Eiji Kakazu, 195740
Onset of, but not Capacity beyond, Anaerobic Threshold (AT) during Graded Treadmill Testing is Reduced in Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Patrick Austin, 195741
Noninvasive Indices for the Prediction of Presence and Severity of Nonalcoholic Fatty Liver Disease in Patients with Chronic Kidney Disease
AASLD LiverLearning®, Hwi Young Kim, 195742
Cirrhosis and Aging Concomitantly Affect Brain Inflammation and Neurotransmitter Expression: Implications for Hepatic Encephalopathy in Elderly Cirrhotics
AASLD LiverLearning®, Jasmohan Bajaj, 195497
Evaluation of the Thyroid Receptor Agonist VK2809 on Liver Disease in DIO-NASH Mice
AASLD LiverLearning®, Brian Lian, 195498
Development and Characterization of High Fat Diet-induced Non-human Primate Models of Liver Diseases: Steatosis, NASH and Fibrosis
AASLD LiverLearning®, Lichuan Yang, 195499
TRAIL Deletion Prevents Liver, but Not Adipose Tissue, Inflammation during Murine Diet-Induced Obesity
AASLD LiverLearning®, Petra Hirsova, 195500
A study of the genetic variants associated with non-alcoholic fatty liver disease in ethnic-Chinese population in Singapore
AASLD LiverLearning®, Guan Huei Lee, 195756
Hispanic Ethnicity Is Associated with Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Women With Polycystic Ovary Syndrome (PCOS)
AASLD LiverLearning®, Monika Sarkar, 195757
Effect of semaglutide on alanine aminotransferase in subjects with type 2 diabetes and high cardiovascular risk
AASLD LiverLearning®, Arun Sanyal, 195758
Toll-like receptor 7-mediated Type I Interferon signaling promotes non-alcoholic steatohepatitis by inhibition of regulatory T cell
AASLD LiverLearning®, Yoon Seok Roh, 195513
Sphingomyelin synthase 2 contributes to liver fibrosis progression through altered hepatic sphingosine 1-phospate metabolism in mice
AASLD LiverLearning®, Masayuki Sugimoto, 195514
Sphingosine 1-Phosphate (S1P) and its receptor S1PR2 regulate ductular reaction in a mouse model of nonalcoholic steatohepatitis
AASLD LiverLearning®, Kato Hideaki, 195515
Examining Changes in Liver Enzymes in Patients with Obesity Treated with Lorcaserin: A Post-hoc Analysis of the Pivotal Studies
AASLD LiverLearning®, Russell Knoth, 195772
PNPLA-3 gene polymorphism in diabetic patients - a prognostic marker of both liver disease and diabetes complications
AASLD LiverLearning®, Cristiane Villela-Nogueira, 195773
Fatigue and Activity Level Self-Reports Do Not Predict Exercise Tolerance in Subjects with Non-alcoholic Fatty Liver Disease (NAFLD) Patients
AASLD LiverLearning®, Zobair Younossi, 195774
Modulation of Nonalcoholic Fatty Liver Disease and Steatohepatitis by Targeting the Retinoic Acid Receptors Alpha and Beta
AASLD LiverLearning®, Melis Marta, 195529
YH25724, a novel long-acting GLP-1/FGF21 dual agonist, induces body weight loss and improves glucose and lipid metabolism in obese diabetic monkeys
AASLD LiverLearning®, JUN HWAN KIM, 195530
Hepatic Signature Expression of miR-199a-5p, miR-21-3p, miR-224-5p, and miR-150-5p Detected by NextSeq Technology are Independently Associated with Fibrosis in Non-alcoholic Steatohepatitis (NASH) and Non-alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Zobair Younossi, 195545
Heritable variation of redox homeostasis is a potential risk factor for biliary disease
AASLD LiverLearning®, Xiao Zhao, 195290
Identification of Novel Targets For Nonalcoholic Steatohepatitis Using A Human Surrogate System
AASLD LiverLearning®, Banumathi Cole, 195546
Decreased Phosphatidylcholine (PC) in Non-alcoholic Steatohepatitis (NASH) livers is attributed to the reduction of long chain PC fraction and is Associated with ELOVL6 Genetic Variants
AASLD LiverLearning®, Zhipeng Liu, 195547
Targeting YAP in Cholangiocarcinoma (CCA) induces cell senescence while blocking cell proliferation
AASLD LiverLearning®, Massimiliano Cadamuro, 195292
Role of CREB regulated transcription co-activator 3 (Crtc3) in fasting and diet-induced fatty liver
AASLD LiverLearning®, Tin Than, 195561
Coffee mediated effects on transcriptional regulation of human UDP-glucuronosyltransferases (UGTs) during obstructive cholestasis (BDL) in a humanized transgenic UGT1A mouse model
AASLD LiverLearning®, Steffen Landerer, 195306
Inhibition of microRNA-200b/c improved liver inflammation and liver fibrosis in NASH model mice
AASLD LiverLearning®, Masato Nakamura, 195562
Treatment of cholestatic bile duct ligated (BDL) mice with a menin-MLL inhibitor reduces biliary damage and liver fibrosis
AASLD LiverLearning®, Laurent Ehrlich, 195307
Acute mitochondrial pyruvate carrier-dependent and -independent effects of MSDC-0602 in hepatocytes on insulin sensitivity and NASH endpoints in mice.
AASLD LiverLearning®, Brian Finck, 195563
Obesity exacerbates the neurological impairments associated to hepatic encephalopathy in chronic liver disease
AASLD LiverLearning®, Rafael Ochoa-Sanchez, 195308
Long-term follow-up of diet-induced murine NASH models with hyperinsulinemia, steatohepatitis, and fibrosis
AASLD LiverLearning®, Naomichi Abe, 195577
Chronic kidney disease in cirrhosis: Patient characteristics and its effects on patient outcomes
AASLD LiverLearning®, Florence Wong, 195322
Reintroduction of mast cells induces biliary damage/senescence, steatosis, inflammation and hepatic fibrosis in mast cell deficient mice fed high fat diet
AASLD LiverLearning®, Lindsey Kennedy, 195578
The Impact of Medical Complications in the Treatment of Decompensated Cirrhosis and Ascites Requiring Large Volume Paracentesis
AASLD LiverLearning®, Michael Runken, 195323
Portal fibrosis predominantly in MCD-induce juvenile Nonalcoholic Steatohepatitis mouse models
AASLD LiverLearning®, feng liu, 195579
Acute kidney injury on the transplant waiting list: Effect on post-liver transplantation renal and patient outcomes
AASLD LiverLearning®, Shuet Fong Neong, 195324